John Santilli quoted in Modern Medicine: Olysio indication expanded for combo use with Sovaldi in hepatitis C

“[Hepatitis C] is a very competitive market, as a number of companies are looking to compete with Gilead’s products due to the large population of patients and the high earnings potential for drug sales,” said John Santilli, of Access Market Intelligence, which provides market intelligence to the pharmaceutical and healthcare industries. 

Read more here:

http://managedhealthcareexecutive.modernmedicine.com/managed-healthcare-executive/news/top-five-industry-challenges-2015?page=0,7